Skip to main content
SpringerLink
Log in

Safety Considerations in Drug Treatment of Depression in HIV-Positive Patients

An Updated Review

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Major depressive disorder (MDD) is one of the most prevalent illnesses associated with HIV infection, and negatively affects medication adherence, disease progression and mortality in HIV disease. Co-morbid treatment of major depression in HIV disease is the optimal therapeutic approach, but discriminating MDD from normal fluctuations in mood state, personality or physiology is difficult. Definitive diagnosis of MDD is critical for drug safety and for avoiding unnecessary exposure to psychotropic medications. HIV patients respond to antidepressant treatment like the general population, and medication adverse effects and patient adherence are the best predictors of treatment outcome.

This review attempts to assist the medical provider with the diagnosis and treatment of MDD in HIV patients. We outline the initial steps in screening and psychiatric referral, the antidepressants that are particularly useful in HIV-infected patients, and the adverse effects and pharmacological strategies for overcoming potential barriers to medication adherence. Potential interactions between the various classes of antidepressants and HIV/antiretroviral therapy, as well as management of HIV medication-related psychiatric adverse effects, are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II

Similar content being viewed by others

References

  1. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001 Aug; 58(8): 721–8

    Article  PubMed  CAS  Google Scholar 

  2. Kilbourne AM, Justice AC, Rabeneck L, et al. General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. J Clin Epidemiol 2001 Dec; 54 Suppl. 1: S22–8

    Article  PubMed  Google Scholar 

  3. Cysique LA, Deutsch R, Atkinson JH, et al. Incident major depression does not affect neuropsychological functioning in HIV-infected men. J Int Neuropsychol Soc 2007 Jan; 13(1): 1–11

    Article  PubMed  Google Scholar 

  4. Gibbie T, Hay M, Hutchison CW, et al. Depression, social support and adherence to highly active antiretroviral therapy in people living with HIV/AIDS. Sex Health 2007 Dec; 4(4): 227–32

    Article  PubMed  Google Scholar 

  5. Lyketsos CG, Hutton H, Fishman M, et al. Psychiatric morbidity on entry to an HIV primary care clinic. AIDS 1996 Aug; 10(9): 1033–9

    Article  PubMed  CAS  Google Scholar 

  6. Ellis RJ, Rosario D, Clifford DB, et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol 2010 May; 67(5): 552–8

    Article  PubMed  Google Scholar 

  7. Orlando M, Burnam MA, Beckman R, et al. Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: results from the HIV Cost and Services Utilization Study. Int J Methods Psychiatr Res 2002; 11(2): 75–82

    Article  PubMed  Google Scholar 

  8. Lima VD, Geller J, Bangsberg DR, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS 2007 May 31; 21(9): 1175–83

    Article  PubMed  Google Scholar 

  9. Journot V, Chene G, De Castro N, et al. Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099. Clin Infect Dis 2006 Jun 15; 42(12): 1790–9

    Article  PubMed  CAS  Google Scholar 

  10. Alciati A, Starace F, Scaramelli B, et al. Has there been a decrease in the prevalence of mood disorders in HIV-seropositive individuals since the introduction of combination therapy? Eur Psychiatry 2001 Dec; 16(8): 491–1

  11. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001 Mar 21; 285(11): 1466–74

    Article  PubMed  CAS  Google Scholar 

  12. Lyketsos CG, Hoover DR, Guccione M, et al. Changes in depressive symptoms as AIDS develops. The Multicenter AIDS Cohort Study. Am J Psychiatry 1996 Nov; 153(11): 1430–7

    PubMed  CAS  Google Scholar 

  13. Lyketsos CG, Hoover DR, Guccione M. Depression and survival among HIV-infected persons. JAMA 1996 Jan 3; 275(1): 35–6

    Article  PubMed  CAS  Google Scholar 

  14. Hughes J, Jelsma J, Maclean E, et al. The health-related quality of life of people living with HIV/AIDS. Disabil Rehabil 2004 Mar 18; 26(6): 371–6

    Article  PubMed  Google Scholar 

  15. Elliott AJ, Russo J, Roy-Byrne PP. The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. Gen Hosp Psychiatry 2002 Jan–Feb; 24(1): 43–7

    Article  PubMed  Google Scholar 

  16. Patterson K, Young C, Woods SP, et al. Screening for major depression in persons with HIV infection: the concurrent predictive validity of the Profile of Mood States Depression-Dejection Scale. Int J Methods Psychiatr Res 2006 Jun; 15(2): 75–82

    Article  PubMed  Google Scholar 

  17. Marwick KF, Kaaya SF. Prevalence of depression and anxiety disorders in HIV-positive outpatients in rural Tanzania. AIDS Care 2010 Apr; 22(4): 415–9

    Article  PubMed  Google Scholar 

  18. Lyketsos CG, Hanson A, Fishman M, et al. Screening for psychiatric morbidity in a medical outpatient clinic for HIV infection: the need for a psychiatric presence. Int J Psychiatry Med 1994; 24(2): 103–13

    Article  PubMed  CAS  Google Scholar 

  19. Lenz G, Demal U. Quality of life in depression and anxiety disorders: an exploratory follow-up study after intensive inpatient cognitive behaviour therapy. Psychopathology 2000 Nov–Dec; 33(6): 297–302

    Article  PubMed  CAS  Google Scholar 

  20. Meltzer-Brody S, Davidson JR. Completeness of response and quality of life in mood and anxiety disorders. Depress Anxiety 2000; 12 Suppl. 1: 95–101

    Article  Google Scholar 

  21. Azar MM, Springer SA, Meyer JP, et al. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend 2010 Dec 1; 112(3): 173–93

    Article  Google Scholar 

  22. DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002 Sep; 40(9): 794–811

    Article  PubMed  Google Scholar 

  23. Holmes J, House A. Psychiatric illness predicts poor outcome after surgery for hip fracture: a prospective cohort study. Psychol Med 2000 Jul; 30(4): 921–9

    Article  PubMed  CAS  Google Scholar 

  24. Plummer ML, Watson-Jones D, Lees S, et al. A qualitative study of participant adherence in a randomized controlled trial of herpes suppressive therapy for HIV prevention in Tanzania. AIDS Care 2010 Apr; 22(4): 499–508

    Article  PubMed  Google Scholar 

  25. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999 Oct; 29(4): 824–30

    Article  PubMed  CAS  Google Scholar 

  26. Vedhara K, Schifitto G, McDermott M. Disease progression in HIV-positive women with moderate to severe immunosuppression: the role of depression. Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Behav Med 1999; 25(1): 43–7

    Article  PubMed  CAS  Google Scholar 

  27. Rabkin JG, Williams JB, Remien RH, et al. Depression, distress, lymphocyte subsets, and human immunodeficiency virus symptoms on two occasions in HIV-positive homosexual men. Arch Gen Psychiatry 1991; 48(2): 111–9

    Article  PubMed  CAS  Google Scholar 

  28. Leserman J, Petitto J, Gu H, et al. Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol Med 2002; 32(6): 1059–73

    Article  PubMed  CAS  Google Scholar 

  29. Leserman J. HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiatry 2003 Aug 1; 54(3): 295–306

    Article  PubMed  Google Scholar 

  30. Leserman J. Role of depression, stress, and trauma in HIV disease progression. Psychosom Med 2008 Jun; 70(5): 539–45

    Article  PubMed  Google Scholar 

  31. Cook JA, Grey D, Burke J, et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health 2004 Jul; 94(7): 1133–40

    Article  PubMed  Google Scholar 

  32. Riley ED, Wu AW, Perry S, et al. Depression and drug use impact health status among marginally housed HIV-infected individuals. AIDS Patient Care STDS 2003 Aug; 17(8): 401–6

    Article  PubMed  Google Scholar 

  33. Cooperman NA, Simoni JM. Suicidal ideation and attempted suicide among women living with HIV/AIDS. J Behav Med 2005 Apr; 28(2): 149–56

    Article  PubMed  Google Scholar 

  34. Haller DL, Miles DR. Suicidal ideation among psychiatric patients with HIV: psychiatric morbidity and quality of life. AIDS Behav 2003 Jun; 7(2): 101–8

    Article  PubMed  Google Scholar 

  35. Carrico AW, Antoni MH, Duran RE, et al. Reductions in depressed mood and denial coping during cognitive behavioral stress management with HIV-positive gay men treated with HAART. Ann Behav Med 2006 Apr; 31(2): 155–64

    Article  PubMed  Google Scholar 

  36. Carrico AW, Johnson MO, Moskowitz JT, et al. Affect regulation, stimulant use, and viral load among HIV-positive persons on anti-retroviral therapy. Psychosom Med 2007 Nov; 69(8): 785–92

    Article  PubMed  Google Scholar 

  37. Alciati A, Gallo L, Monforte AD, et al. Major depression-related immunological changes and combination antiretroviral therapy in HIV-seropositive patients. Hum Psychopharmacol 2007 Jan; 22(1): 33–40

    Article  PubMed  Google Scholar 

  38. van der Lee MJ, Blenke AA, Rongen GA, et al. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrob Agents Chemother 2007 Nov; 51(11): 4098–104

    Article  PubMed  CAS  Google Scholar 

  39. Sledjeski EM, Delahanty DL, Bogart LM. Incidence and impact of posttraumatic stress disorder and comorbid depression on adherence to HAART and CD4+ counts in people living with HIV. AIDS Patient Care STDS 2005 Nov; 19(11): 728–36

    Article  PubMed  Google Scholar 

  40. van Servellen G, Chang B, Garcia L, et al. Individual and system level factors associated with treatment non-adherence in human immunodeficiency virus-infected men and women. AIDS Patient Care STDS 2002 Jun; 16(6): 269–81

    Article  PubMed  Google Scholar 

  41. Pieper AA, Treisman GJ. Drug treatment of depression in HIV-positive patients: safety considerations. Drug Saf 2005; 28(9): 753–62

    Article  PubMed  CAS  Google Scholar 

  42. Angelino AF, Treisman GJ. Issues in co-morbid severe mental illnesses in HIV infected individuals. Int Rev Psychiatry 2008 Feb; 20(1): 95–101

    Article  PubMed  Google Scholar 

  43. Rourke SB, Halman MH, Bassel C. Neurocognitive complaints in HIV-infection and their relationship to depressive symptoms and neuropsychological functioning. J Clin Exp Neuropsychol 1999; 21(6): 737–56

    Article  PubMed  CAS  Google Scholar 

  44. Millikin CP, Rourke SB, Halman MH, et al. Fatigue in HIV/AIDS is associated with depression and subjective neurocognitive complaints but not neuropsychological functioning. J Clin Exp Neuropsychol 2003; 25(2): 201–15

    Article  PubMed  Google Scholar 

  45. Goroll AH, Mulley AG. Primary care medicine: office evaluation and management of the adult patient. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2009

    Google Scholar 

  46. US Department of Health & Human Services, Agency for Healthcare Research and Quality. Guideline summary [online]. Available from URL: http://www.guideline.gov/content.aspx?id=12811 [Accessed 2011 May 31]

  47. Fekete E, Geaghan TR, Druley JA. Affective and behavioural reactions to positive and negative health-related social control in HIV+ men. Psychol Health 2009; 24(5): 501–15

    Article  PubMed  Google Scholar 

  48. Hudson JI, Mangweth B, Pope Jr HG, et al. Family study of affective spectrum disorder. Arch Gen Psychiatry 2003; 60: 170–7

    Article  PubMed  Google Scholar 

  49. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. American Psychiatric Association; 2000

  50. Freudenreich O, Goforth HW, Cozza KL, et al. Psychiatritreatment of persons with HIV/AIDS: an HIV-psychiatry consensus survey of current practices. Psychosomatics 2010 Nov; 51(6): 480–8

    PubMed  CAS  Google Scholar 

  51. Bogdanova Y, Diaz-Santos M, Cronin-Golomb A. Neurocognitive correlates of alexithymia in asymptomatic individuals with HIV. Neuropsychologia 2010 Apr; 48(5): 1295–304

    Article  PubMed  Google Scholar 

  52. Paul RH, Brickman AM, Navia B, et al. Apathy is associated with volume of the nucleus accumbens in patients infected with HIV. J Neuropsychiatry Clin Neurosci 2005; 17(2): 167–71

    Article  PubMed  Google Scholar 

  53. Tsao JC, Dobalian A, Naliboff BD. Panic disorder and pain in a national sample of persons living with HIV. Pain 2004; 109(1–2): 172–80

    Article  PubMed  Google Scholar 

  54. Ginzburg K, Butler LD, Giese-Davis J, et al. Shame, guilt, and posttraumatic stress disorder in adult survivors of childhood sexual abuse at risk for human immunodeficiency virus: outcomes of a randomized clinical trial of group psychotherapy treatment. J Nerv Ment Dis 2009; 197(7): 536–42

    Article  PubMed  Google Scholar 

  55. Jong E, Oudhoff LA, Epskamp C, et al. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era. AIDS 2010 Jun 19; 24(10): 1387–405

    Article  PubMed  CAS  Google Scholar 

  56. Castellon SA, Hardy DJ, Hinkin CH, et al. Components of depression in HIV-1 infection: their differential relationship to neurocognitive performance. J Clin Exp Neuropsychol 2006 Apr; 28(3): 420–37

    Article  PubMed  Google Scholar 

  57. Pugh K, Riccio M, Jadresic D, et al. A longitudinal study of the neuropsychiatric consequences of HIV-1 infection in gay men: II. Psychological and health status at baseline and at 12-month follow-up. Psychol Med 1994 Nov; 24(4): 897–904

    Article  PubMed  CAS  Google Scholar 

  58. Beck AT, Ward C, Mendelson M. Beck depression inventory (BDI). Arch Gen Psychiatry 1961; 4: 561–71

    Article  PubMed  CAS  Google Scholar 

  59. Goldberg DP. General health questionnaire (GHQ-12). Windsor: NFER-Nelson, 1992

    Google Scholar 

  60. Treisman G, Fishman M, Lyketsos C, et al. Evaluation and treatment of psychiatric disorders associated with HIV infection. Res Publ Assoc Res Nerv Ment Dis 1994; 72: 239–50

    PubMed  CAS  Google Scholar 

  61. Cheer SM, Goa KL. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs 2001; 61(1): 81–110

    Article  PubMed  CAS  Google Scholar 

  62. Grassi L, Mondardini D, Pavanati M, et al. Suicide probability and psychological morbidity secondary to HIV infection: a control study of HIV-seropositive, hepatitis C virus (HCV)-seropositive and HIV/HCV-seronegative injecting drug users. J Affect Disord 2001 May; 64(2–3): 195–202

    Article  PubMed  CAS  Google Scholar 

  63. Rabkin JG, Rabkin R, Harrison W, et al. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry 1994 Apr; 151(4): 516–23

    PubMed  CAS  Google Scholar 

  64. De Wit S, Cremers L, Hirsch D, et al. Efficacy and safety of trazodone versus clorazepate in the treatment of HIV-positive subjects with adjustment disorders: a pilot study. J Int Med Res 1999 Sep–Oct; 27(5): 223–32

    PubMed  CAS  Google Scholar 

  65. Kristiansen JE, Hansen JB. Inhibition of HIV replication by neuroleptic agents and their potential use in HIV infected patients with AIDS related dementia. Int J Antimicrob Agents 2000 Apr; 14(3): 209–13

    Article  PubMed  CAS  Google Scholar 

  66. Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials 2005 Jul–Aug; 6(4): 187–96

    Article  PubMed  Google Scholar 

  67. Treisman GJ, Angelino AF, Hutton HE. Psychiatric issues in the management of patients with HIV infection. JAMA 2001 Dec 12; 286(22): 2857–64

    Article  PubMed  CAS  Google Scholar 

  68. Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry 1999 Jan; 156(1): 101–7

    PubMed  CAS  Google Scholar 

  69. Rabkin JG, Rabkin R, Wagner G. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. J Clin Psychiatry 1994 Mar; 55(3): 92–7

    PubMed  CAS  Google Scholar 

  70. Sherr L, Harding R, Lampe F, et al. Clinical and behavioural aspects of aging with HIV infection. Psychol Health Med 2009 May; 14(3): 273–9

    Article  PubMed  Google Scholar 

  71. Omonuwa TS, Goforth HW, Preud’homme X, et al. The pharmacologic management of insomnia in patients with HIV. J Clin Sleep Med 2009 Jun 15; 5(3): 251–62

    PubMed  Google Scholar 

  72. Letendre SL, Ellis RJ, Ances BM, et al. Neurologic complications of HIV disease and their treatment. Top HIV Med 2007 Apr–May; 18(2): 45–55

    Google Scholar 

  73. Maina G, Albert U, Salvi V, et al. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry 2004 Oct; 65(10): 1365–71

    Article  PubMed  CAS  Google Scholar 

  74. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010 Oct; 71(10): 1259–72

    Article  PubMed  Google Scholar 

  75. Daly EJ, Trivedi MH, Fava M, et al. The relationship etween adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study. J Clin Psychopharmacol 2011 Feb; 31(1): 31–8

    Article  PubMed  CAS  Google Scholar 

  76. Purcell DW, Wolitski RJ, Hoff CC, et al. Predictors of the use of viagra, testosterone, and antidepressants among HIV-seropositive gay and bisexual men. AIDS 2005 Apr; 19 Suppl. 1: S57–66

    Article  PubMed  CAS  Google Scholar 

  77. Richardson D, Goldmeier D. Pharmacological treatment for premature ejaculation. Int J STD AIDS 2005 Oct; 16(10): 709–11

    Article  PubMed  Google Scholar 

  78. Woodrum ST, Brown CS. Management of SSRI-induced sexual dysfunction. Ann Pharmacother 1998 Nov; 32(11): 1209–15

    Article  PubMed  CAS  Google Scholar 

  79. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005 Aug; 66(8): 974–81

    Article  PubMed  CAS  Google Scholar 

  80. Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother 2006 Sep; 40(9): 1618–22

    Article  PubMed  CAS  Google Scholar 

  81. Arinzon ZH, Lehman YA, Fidelman ZG, et al. Delayed recurrent SIADH associated with SSRIs. Ann Pharmacother 2002 Jul–Aug; 36(7–8): 1175–7

    Article  PubMed  Google Scholar 

  82. Rabkin JG, Wagner GJ, McElhiney MC, et al. Testosterone versus fluoxetine for depression and fatigue in HIV/ AIDS: a placebo-controlled trial. J Clin Psychopharmacol 2004 Aug; 24(4): 379–85

    Article  PubMed  CAS  Google Scholar 

  83. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 2009 Jan; 25(1): 161–75

    Article  PubMed  CAS  Google Scholar 

  84. Evans DL, Lynch KG, Benton T, et al. Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndrome. Biol Psychiatry 2008 May 1; 63(9): 899–905

    Article  PubMed  CAS  Google Scholar 

  85. Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008 Feb 15; 63(4): 424–34

    Article  PubMed  CAS  Google Scholar 

  86. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010 Sep; 17(9): 1113-e88

    Article  PubMed  CAS  Google Scholar 

  87. Thompson A, Silverman B, Dzeng L, et al. Psychotropic medications and HIV. Clin Infect Dis 2006 May 1; 42(9): 1305–10

    Article  PubMed  CAS  Google Scholar 

  88. Henry JA. Epidemiology and relative toxicity of antidepressant drugs in overdose. Drug Saf 1997 Jun; 16(6): 374–90

    Article  PubMed  CAS  Google Scholar 

  89. Marcus M, Maida CA, Freed JR, et al. Oral white patches in a national sample of medical HIV patients in the era of HAART. Community Dent Oral Epidemiol 2005 Apr; 33(2): 99–106

    Article  PubMed  Google Scholar 

  90. Marcus M, Yamamoto JM, Der-Martirosian C, et al. National estimates of out-of-pocket dental costs for HIV-infected users of medical care. J Am Dent Assoc 2005 Oct; 136(10): 1406–14

    PubMed  Google Scholar 

  91. von Moltke LL, Greenblatt DJ, Duan SX, et al. Inhibition of desipramine hydroxylation (cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci 1998 Oct; 87(10): 1184–9

    Article  Google Scholar 

  92. Lanzafame M, Ferrari S, Lattuada E, et al. Mirtazapine in an HIV-1 infected patient with progressive multifocal leukoencephalopathy. Infez Med 2009 Mar; 17(1): 35–7

    PubMed  CAS  Google Scholar 

  93. Elliott AJ, Roy-Byrne PP. Mirtazapine for depression in patients with human immunodeficiency virus. J Clin Psychopharmacol 2000 Apr; 20(2): 265–7

    Article  PubMed  CAS  Google Scholar 

  94. Markoula S, Konitsiotis S, Chatzistefanidis D, et al. Akathisia induced by mirtazapine after 20 years of continuous treatment. Clin Neuropharmacol 2010 Jan–Feb; 33(1): 50–1

    Article  PubMed  CAS  Google Scholar 

  95. Hieber R, Dellenbaugh T, Nelson LA. Role of mirtazapine in the treatment of antipsychotic-induced akathisia. Ann Pharmacother 2008 Jun; 42(6): 841–6

    Article  PubMed  CAS  Google Scholar 

  96. Poyurovsky M, Pashinian A, Weizman R, et al. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia: a randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry 2006 Jun 1; 59(11): 1071–7

    Article  PubMed  CAS  Google Scholar 

  97. Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 2009 Feb; 66(2): 255–8

    Article  PubMed  Google Scholar 

  98. Elliott AJ, Russo J, Bergam K, et al. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. J Clin Psychiatry 1999 Apr; 60(4): 226–31

    Article  PubMed  CAS  Google Scholar 

  99. Learned-Coughlin SM, Bergstrom M, Savitcheva I, et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 2003 Oct 15; 54(8): 800–5

    Article  PubMed  CAS  Google Scholar 

  100. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000 Oct; 295(1): 321–7

    PubMed  CAS  Google Scholar 

  101. Hesse LM, von Moltke LL, Shader RI, et al. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 2001 Feb; 29(2): 100–2

    PubMed  CAS  Google Scholar 

  102. Robertson SM, Maldarelli F, Natarajan V, et al. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 2008 Dec 15; 49(5): 513–9

    Article  PubMed  CAS  Google Scholar 

  103. Lavrut T, Garraffo R, Ferrando S, et al. Effect of tipranavir/ritonavir treatment on the steady-state pharmacokinetics of bupropion in healthy volunteers [abstract no. P4.3/03]. 11th European AIDS Conference; 2007 Oct 24–27; Madrid

  104. Pisani F, Oteri G, Costa C, et al. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002; 25(2): 91–110

    Article  PubMed  CAS  Google Scholar 

  105. Ahern TH, Javors MA, Eagles DA, et al. The effects of chronic norepinephrine transporter inactivation on seizure susceptibility in mice. Neuropsychopharmacology 2006 Apr; 31(4): 730–8

    Article  PubMed  CAS  Google Scholar 

  106. GlaxoSmithKline. Wellbutrin XL® prescribing information [online]. Available from URL: http://us.gsk.com/products/assets/us_wellbutrinXL.pdf [Accessed 2011 May 31]

  107. Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med 2010 Dec; 77(12): 859–82

    Article  PubMed  Google Scholar 

  108. Schifitto G, Yiannoutsos CT, Ernst T, et al. Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology 2009 Dec 8; 73(23): 1975–81

    Article  PubMed  CAS  Google Scholar 

  109. Schifitto G, Zhang J, Evans SR, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 2007 Sep 25; 69(13): 1314–21

    Article  PubMed  Google Scholar 

  110. Evans SR, Yeh TM, Sacktor N, et al. Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials 2007 Nov–Dec; 8(6): 437–46

    Article  PubMed  Google Scholar 

  111. Sacktor N, Schifitto G, McDermott MP, et al. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 2000 Jan 11; 54(1): 233–5

    Article  PubMed  CAS  Google Scholar 

  112. Koutsilieri E, Scheller C, Sopper S, et al. Selegiline completely restores choline acetyltransferase activity deficits in simian immunodeficiency infection. Eur J Pharmacol 2001 Jan 5; 411(1–2): R1–2

    Article  PubMed  CAS  Google Scholar 

  113. Koutsilieri E, Sopper S, Scheller C, et al. Involvement of dopamine in the progression of AIDS dementia complex. J Neural Transm 2002b Mar; 109(3): 399–410

    Article  CAS  Google Scholar 

  114. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000 Jun; 61(6): 436–40

    Article  PubMed  CAS  Google Scholar 

  115. Rabkin JG, McElhiney MC, Rabkin R, et al. Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. J Clin Psychiatry 2010 Jun; 71(6): 707–15

    Article  PubMed  CAS  Google Scholar 

  116. McElhiney M, Rabkin J, Van Gorp W, et al. Modafinil effects on cognitive function in HIV+ patients treated for fatigue: a placebo controlled study. J Clin Exp Neuropsychol 2010 Jun; 32(5): 474–80

    Article  PubMed  Google Scholar 

  117. McElhiney MC, Rabkin JG, Rabkin R, et al. Provigil (modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV+ gay men: a pilot study. Am J Drug Alcohol Abuse 2009; 35(1): 34–7

    Article  PubMed  Google Scholar 

  118. Breitbart W, Rosenfeld B, Kaim M, et al. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001 Feb 12; 161(3): 411–20

    Article  PubMed  CAS  Google Scholar 

  119. Rabkin JG, McElhiney MC, Rabkin R, et al. Modafinil treatment for fatigue in HIV+ patients: a pilot study. J Clin Psychiatry 2004 Dec; 65(12): 1688–95

    Article  PubMed  CAS  Google Scholar 

  120. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001 Jan; 158(1): 131–4

    Article  PubMed  CAS  Google Scholar 

  121. Schifitto G, Zhong J, Gill D, et al. Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol 2009 Apr; 15(2): 176–86

    Article  PubMed  CAS  Google Scholar 

  122. Letendre SL, Woods SP, Ellis RJ, et al. Lithium improves HIV-associated neurocognitive impairment. AIDS 2006 Sep 11; 20(14): 1885–8

    Article  PubMed  CAS  Google Scholar 

  123. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment: an effective prescription for treatment-refractory depression. Arch Gen Psychiatry 1983 Dec; 40(12): 1335–42

    Article  PubMed  CAS  Google Scholar 

  124. Nierenberg AA, Price LH, Charney DS, et al. After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depression. J Affect Disord 1990 Mar; 18(3): 167–75

    Article  PubMed  CAS  Google Scholar 

  125. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression: a controlled trial using lithium in low and normal doses. Br J Psychiatry 1993 May; 162: 634–40

    Article  PubMed  CAS  Google Scholar 

  126. Ogura C, Okuma T, Uchida Y, et al. Combined thyroid (triiodothyronine)-tricyclic antidepressant treatment in depressive states. Folia Psychiatr Neurol Jpn 1974; 28(3): 179–86

    PubMed  CAS  Google Scholar 

  127. Perry EB, Berman RM, Sanacora G, et al. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. J Clin Psychiatry 2004 Feb; 65(2): 238–43

    Article  PubMed  CAS  Google Scholar 

  128. Sheehan NL, Brouillette MJ, Delisle MS, et al. Possible interaction between lopinavir/ritonavir and valproic acid exacerbates bipolar disorder. Ann Pharmacother 2006 Jan; 40(1): 147–50

    Article  PubMed  Google Scholar 

  129. Berman RM, Anand A, Cappiello A, et al. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol Psychiatry 1999 May 1; 45(9): 1170–7

    Article  PubMed  CAS  Google Scholar 

  130. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009 Apr; 14(4): 197–206

    PubMed  Google Scholar 

  131. Ances BM, Letendre SL, Alexander T, et al. Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders. Int Rev Psychiatry 2008 Feb; 20(1): 89–93

    Article  PubMed  Google Scholar 

  132. Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993 May; 50(5): 387–93

    Article  PubMed  CAS  Google Scholar 

  133. Nelson JC. Augmentation strategies in depression 2000. J Clin Psychiatry 2000; 61 Suppl. 2: 13–9

    Google Scholar 

  134. Bates DE, Herman RJ. Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir. Ann Pharmacother 2006 Jun; 40(6): 1190–5

    Article  PubMed  Google Scholar 

  135. Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007 Dec; 116(3): 496–526

    Article  PubMed  CAS  Google Scholar 

  136. Treisman GJ, Kaplin AI. Neurologic and psychiatric complications of antiretroviral agents. AIDS 2002 Jun 14; 16(9): 1201–15

    Article  PubMed  CAS  Google Scholar 

  137. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 2003 Apr; 25(4): 1200–10

    Article  PubMed  CAS  Google Scholar 

  138. Ouellet D, Hsu A, Qian J, et al. Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrob Agents Chemother 1998 Dec; 42(12): 3107–12

    PubMed  CAS  Google Scholar 

  139. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 2003 Apr; 43(4): 414–22

    Article  PubMed  CAS  Google Scholar 

  140. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008 Jul; 42(7): 1048–59

    Article  PubMed  CAS  Google Scholar 

  141. McArthur JC, Brew BJ. HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS 2010 Jun 1; 24(9): 1367–1

  142. Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care 2009 Aug; 21(8): 976–83

    Article  PubMed  Google Scholar 

  143. Treisman G, Angelino A. Interrelation between psychiatric disorders and the prevention and treatment of HIV infection. Clin Infect Dis 2007 Dec 15; 45 Suppl. 4: S313–7

    Article  PubMed  Google Scholar 

  144. Carvalho FC, Barbi MS, Sarmento VH, et al. Surfactant systems for nasal zidovudine delivery: structural, rheological and mucoadhesive properties. J Pharm Pharmacol 2010 Apr; 62(4): 430–9

    PubMed  CAS  Google Scholar 

  145. Jena A, Sachdeva RK, Sharma A, et al. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study. J Int Assoc Physicians AIDS Care (Chic) 2009 Sep–Oct; 8(5): 318–22

    Article  Google Scholar 

  146. Maxwell S, Scheftner WA, Kessler HA, et al. Manic syndrome associated with zidovudine treatment. JAMA 1988 Jun 17; 259(23): 3406–7

    Article  PubMed  CAS  Google Scholar 

  147. Cruess DG, Evans DL, Repetto MJ, et al. Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biol Psychiatry 2003 Aug 1; 54(3): 307–16

    Article  PubMed  Google Scholar 

  148. Gutierrez-Valencia A, Viciana P, Palacios R, et al. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Ann Intern Med 2009 Aug 4; 151(3): 149–56

    PubMed  Google Scholar 

  149. Arendt G, de Nocker D, von Giesen HJ, et al. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf 2007 Mar; 6(2): 147–54

    Article  PubMed  CAS  Google Scholar 

  150. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001 Jan 5; 15(1): 71–5

    Article  PubMed  CAS  Google Scholar 

  151. DiGiacinto JL, Chan-Tack KM, Robertson SM, et al. Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampin. J Clin Pharmacol 2008 Apr; 48(4): 518–23

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Crystal C. Watkins &  Glenn J. Treisman

  2. Departments of Psychiatry and Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Andrew A. Pieper

  3. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Glenn J. Treisman

Authors
  1. Crystal C. Watkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew A. Pieper
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Glenn J. Treisman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Glenn J. Treisman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Watkins, C.C., Pieper, A.A. & Treisman, G.J. Safety Considerations in Drug Treatment of Depression in HIV-Positive Patients. Drug-Safety 34, 623–639 (2011). https://doi.org/10.2165/11592070-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11592070-000000000-00000

Keywords

Search

Navigation